Kidney stone disease (nephrolithiasis) is a common problem that can be associated with alterations in urinary solute composition including hypercalciuria. Studies suggest that the prevalence of monogenic kidney stone disorders, including renal tubular acidosis with deafness, Bartter syndrome, primary hyperoxaluria and cystinuria, in patients attending kidney stone clinics is ∼15%. However, for the majority of individuals, nephrolithiasis has a multifactorial aetiology involving genetic and environmental factors. Nonetheless, the genetic influence on stone formation in these idiopathic stone formers remains considerable and twin studies estimate a heritability of >45% for nephrolithiasis and >50% for hypercalciuria. The contribution of polygenic influences from multiple loci have been investigated by genome-wide association and candidate gene studies, which indicate that a number of genes and molecular pathways contribute to the risk of stone formation. Genetic approaches, studying both monogenic and polygenic factors in nephrolithiasis, have revealed that the following have important roles in the aetiology of kidney stones: transporters and channels; ions, protons and amino acids; the calcium-sensing receptor (a G protein-coupled receptor) signalling pathway; and the metabolic pathways for vitamin D, oxalate, cysteine, purines and uric acid. These advances, which have increased our understanding of the pathogenesis of nephrolithiasis, will hopefully facilitate the future development of targeted therapies for precision medicine approaches in patients with nephrolithiasis.
Studies suggest that the prevalence of monogenic kidney stone disease in patients attending kidney stone clinics is ∼15%.
For patients without a monogenic cause of nephrolithiasis, the heritability of kidney stone disease and hypercalciuria is >45% and >50%, respectively.
Increased understanding of the genetic factors contributing to kidney stone disease helps to improve our understanding of the pathogenesis of this condition.
Identification of a monogenic cause of kidney stone disease facilitates optimal stone prevention management and identification of associated phenotypes.
Advances in our understanding of the polygenic factors contributing to risk of kidney stone disease might enable a precision medicine approach.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Integrative genome-wide analyses identify novel loci associated with kidney stones and provide insights into its genetic architecture
Nature Communications Open Access 18 November 2023
Cell Death & Disease Open Access 13 October 2023
Causal effects of inflammatory bowel diseases on the risk of kidney stone disease: a two-sample bidirectional mendelian randomization
BMC Urology Open Access 12 October 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Scales, C. D. et al. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160–165 (2012).
Heers, H. & Turney, B. W. Trends in urological stone disease: a 5-year update of hospital episode statistics. BJU Int. 118, 785–789 (2016).
Stamatelou, K. K., Francis, M. E., Jones, C. A., Nyberg, L. M. & Curhan, G. C. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 63, 1817–1823 (2003).
Pearle, M. S. et al. Medical management of kidney stones: AUA Guideline. J. Urol. 192, 316–324 (2014).
Gambaro, G. et al. The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J. Urol. 198, 268–273 (2017).
Goldfarb, D. S. A woman with recurrent calcium phosphate kidney stones. Clin. J. Am. Soc. Nephrol. 7, 1172–1178 (2012).
Ma, Q. et al. Uric acid stones, clinical manifestations and therapeutic considerations. Postgrad. Med. J. 94, 458–462 (2018).
Coe, F. L. Kidney stone disease. J. Clin. Invest. 115, 2598–2608 (2005).
Thomas, K., Wong, K., Withington, J., Bultitude, M. & Doherty, A. Cystinuria—a urologist’s perspective. Nat. Rev. Urol. 11, 270–277 (2014).
Coe, F. L., Worcester, E. M. & Evan, A. P. Idiopathic hypercalciuria and formation of calcium renal stones. Nat. Rev. Nephrol. 12, 519–533 (2016).
Daudon, M. et al. Composition of renal stones currently observed in non-industrialized countries. Prog. Urol. 14, 1151–1161 (2004).
Frick, K. K. Molecular mechanisms of primary hypercalciuria. J. Am. Soc. Nephrol. 14, 1082–1095 (2003).
Resnick, M., Pridgen, D. B. & Goodman, H. O. Genetic predisposition to formation of calcium oxalate renal calculi. N. Engl. J. Med. 278, 1313–1318 (1968).
Curhan, G. C., Willett, W. C., Rimm, E. B. & Stampfer, M. J. Family history and risk of kidney stones. J. Am. Soc. Nephrol. 8, 1568–1573 (1997).
Goldfarb, D. S., Avery, A. R., Beara-Lasic, L., Duncan, G. E. & Goldberg, J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int. Rep. 4, 535–540 (2019).
Goldfarb, D. S., Fischer, M. E., Keich, Y. & Goldberg, J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int. 67, 1053–1061 (2005).
Hunter, D. J. et al. Genetic contribution to renal function and electrolyte balance: a twin study. Clin. Sci. 103, 259–265 (2002).
Hemminki, K. et al. Familial risks in urolithiasis in the population of Sweden. BJU Int. 121, 479–485 (2018).
Halbritter, J. et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J. Am. Soc. Nephrol. 26, 543–551 (2015).
Daga, A. et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 93, 204–213 (2018).
Braun, D. A. et al. Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin. J. Am. Soc. Nephrol. 11, 664–672 (2016).
Türk, C. et al. Guidelines on urolithiasis. Eur. Urol. https://uroweb.org/guideline/urolithiasis (2020).
Pearle, M. S. et al. Medical management of kidney stones. AUA https://www.auanet.org/guidelines/kidney-stones-medical-mangement-guideline (2019).
NICE Guideline. Renal and ureteric stones: assessment and management. BJU Int. 123, 220–232 (2019).
Borghi, L. et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. 155, 839–843 (1996).
Turney, B. W. et al. Diet and risk of kidney stones in the Oxford cohort of the European prospective investigation into cancer and nutrition (EPIC). Eur. J. Epidemiol. 29, 363–369 (2014).
Siener, R., Ebert, D., Nicolay, C. & Hesse, A. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int. 63, 1037–1043 (2003).
Fink, H. A. et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur. Urol. 56, 72–80 (2009).
Ticinesi, A., Nouvenne, A., Maalouf, N. M., Borghi, L. & Meschi, T. Salt and nephrolithiasis. Nephrol. Dial. Transpl. 31, 39–45 (2016).
Bergsland, K. J., Worcester, E. M. & Coe, F. L. Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria. Am. J. Physiol. Renal Physiol. 305, F592–F599 (2013).
Curhan, G. C., Willett, W. C., Speizer, F. E. & Stampfer, M. J. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 59, 2290–2298 (2001).
Reed, B. Y., Heller, H. J., Gitomer, W. L. & Pak, C. Y. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J. Clin. Endocrinol. Metab. 84, 3907–3913 (1999).
Scott, P. et al. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J. Am. Soc. Nephrol. 10, 1007–1013 (1999).
Reed, B. Y. et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J. Clin. Endocrinol. Metab. 87, 1476–1485 (2002).
Wolf, M. T. F. et al. Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2–q34.2 by total genome search for linkage. Nephrol. Dial. Transpl. 20, 909–914 (2005).
Pearce, S. H. et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115–1122 (1996).
Nesbit, M. A. et al. Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368, 2476–2486 (2013).
Gorvin, C. M. et al. Calcium-sensing receptor residues with loss- and gain-of-function mutations are located in regions of conformational change and cause signalling bias. Hum. Mol. Genet. 27, 3720–3733 (2018).
Gorvin, C. M. et al. Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. JCI Insight 2, e91103 (2017).
Hannan, F. M., Babinsky, V. N. & Thakker, R. V. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J. Mol. Endocrinol. 57, R127–R142 (2016).
Yamamoto, M., Akatsu, T., Nagase, T. & Ogata, E. Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85, 4583–4591 (2000).
Vargas-Poussou, R. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J. Am. Soc. Nephrol. 13, 2259–2266 (2002).
Watanabe, S. et al. Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet 360, 692–694 (2002).
BogdanoviĆ, R. et al. A novel CLCN5 mutation in a boy with Bartter-like syndrome and partial growth hormone deficiency. Pediatr. Nephrol. 25, 2363–2368 (2010).
Janssen, A. G. H. et al. Disease-causing dysfunctions of Barttin in Bartter syndrome type IV. J. Am. Soc. Nephrol. 20, 145–153 (2009).
Seyberth, H. W. & Schlingmann, K. P. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr. Nephrol. 26, 1789–1802 (2011).
Lloyd, S. E. et al. A common molecular basis for three inherited kidney stone diseases. Nature 379, 445–449 (1996).
Hoopes, R. R. Jr et al. Dent disease with mutations in OCRL1. Am. J. Hum. Genet. 76, 260–267 (2005).
Edvardsson, V. O. et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr. Nephrol. 28, 1923–1942 (2013).
Devuyst, O. & Thakker, R. V. Dent’s disease. Orphanet J. Rare Dis. 5, 28 (2010).
Wrong, O. M., Norden, A. G. & Feest, T. G. Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 87, 473–493 (1994).
Gorvin, C. M. et al. Receptor-mediated endocytosis and endosomal acidification is impaired in proximal tubule epithelial cells of Dent disease patients. Proc. Natl Acad. Sci. USA 110, 7014–7019 (2013).
Mehta, Z. B., Pietka, G. & Lowe, M. The cellular and physiological functions of the Lowe syndrome protein OCRL1. Traffic 15, 471–487 (2014).
Lowe, C. U., Terrey, M. & MacLachlan, E. A. Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity. AMA Am. J. Dis. Child. 83, 164–184 (1952).
Bockenhauer, D. et al. Renal phenotype in Lowe syndrome: a selective proximal tubular dysfunction. Clin. J. Am. Soc. Nephrol. 3, 1430–1436 (2008).
Hichri, H. et al. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum. Mutat. 32, 379–388 (2011).
Leahey, A. M., Charnas, L. R. & Nussbaum, R. L. Nonsense mutations in the OCRL-1 gene in patients with the oculocerebrorenal syndrome of Lowe. Hum. Mol. Genet. 2, 461–463 (1993).
Blanchard, A. et al. Effect of hydrochlorothiazide on urinary calcium excretion in Dent disease: an uncontrolled trial. Am. J. Kidney Dis. 52, 1084–1095 (2008).
Alonso-Varela, M. et al. Distal renal tubular acidosis. Clinical manifestations in patients with different underlying gene mutations. Pediatr. Nephrol. 33, 1–7 (2018).
Fuster, D. G. & Moe, O. W. Incomplete distal renal tubular acidosis and kidney stones. Adv. Chronic Kidney Dis. 25, 366–374 (2018).
Domrongkitchaiporn, S. et al. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int. 62, 2160–2166 (2002).
Rungroj, N. et al. Distal renal tubular acidosis caused by tryptophan-aspartate repeat domain 72 (WDR72) mutations. Clin. Genet. 94, 409–418 (2018).
Enerbäck, S. et al. Acidosis and deafness in patients with recessive mutations in FOXI1. J. Am. Soc. Nephrol. 29, 1041–1048 (2018).
Agroyannis, B., Koutsikos, D., Tzanatos-Exarchou, H. & Yatzidis, H. Erythrocytosis in type I renal tubular acidosis with nephrocalcinosis. Nephrol. Dial. Transpl. 7, 365–366 (1992).
Wrong, O., Bruce, L. J., Unwin, R. J., Toye, A. M. & Tanner, M. J. A. Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Kidney Int. 62, 10–19 (2002).
Vasuvattakul, S. et al. Autosomal recessive distal renal tubular acidosis associated with Southeast Asian ovalocytosis. Kidney Int. 56, 1674–1682 (1999).
Tanphaichitr, V. S. et al. Novel AE1 mutations in recessive distal renal tubular acidosis. Loss-of-function is rescued by glycophorin A. J. Clin. Invest. 102, 2173–2179 (1998).
Karet, F. E. et al. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat. Genet. 21, 84–90 (1999).
Karet, F. E. et al. Localization of a gene for autosomal recessive distal renal tubular acidosis with normal hearing (rdRTA2) to 7q33-34. Am. J. Hum. Genet. 65, 1656–1665 (1999).
Dhayat, N. A. et al. The vacuolar H+-ATPase B1 subunit polymorphism p.E161K associates with impaired urinary acidification in recurrent stone formers. J. Am. Soc. Nephrol. 27, 1544–1554 (2016).
Sayer, J. A. Progress in understanding the genetics of calcium-containing nephrolithiasis. J. Am. Soc. Nephrol. 28, 748–759 (2017).
Canales, B. K. et al. Polymorphisms in renal ammonia metabolism genes correlate with 24-hour urine pH. Kidney Int. Rep. 2, 1111–1121 (2017).
Vargas-Poussou, R. et al. Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J. Am. Soc. Nephrol. 17, 1437–1443 (2006).
Besouw, M. T. P. et al. Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr. Nephrol. 32, 1–10 (2017).
Palazzo, V. et al. The genetic and clinical spectrum of a large cohort of patients with distal renal tubular acidosis. Kidney Int. 91, 1243–1255 (2017).
Tieder, M. et al. Hereditary hypophosphatemic rickets with hypercalciuria. N. Engl. J. Med. 312, 611–617 (1985).
Chi, Y. et al. A compound heterozygous mutation in SLC34A3 causes hereditary hypophosphatemic rickets with hypercalciuria in a Chinese patient. Bone 59, 114–121 (2014).
Dasgupta, D. et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J. Am. Soc. Nephrol. 25, 2366–2375 (2014).
Acar, S. et al. Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: novel Mutations in PHEX and SLC34A3. PLoS One 13, e0193388 17 (2018).
Braithwaite, V., Pettifor, J. M. & Prentice, A. Novel SLC34A3 mutation causing hereditary hypophosphataemic rickets with hypercalciuria in a Gambian family. Bone 53, 216–220 (2013).
Prié, D. et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N. Engl. J. Med. 347, 983–991 (2002).
Beck, L. et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl Acad. Sci. USA 95, 5372–5377 (1998).
Schlingmann, K. P. et al. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2 A cause idiopathic infantile hypercalcemia. J. Am. Soc. Nephrol. 27, 604–614 (2016).
Oddsson, A. et al. Common and rare variants associated with kidney stones and biochemical traits. Nat. Commun. 6, 7975 (2015).
Urabe, Y. et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet. 8, e1002541 7 (2012).
Karim, Z. et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N. Engl. J. Med. 359, 1128–1135 (2008).
Gisler, S. M. et al. Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J. Biol. Chem. 276, 9206–9213 (2001).
Shenolikar, S., Voltz, J. W., Minkoff, C. M., Wade, J. B. & Weinman, E. J. Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc. Natl Acad. Sci. USA 99, 11470–11475 (2002).
Bergwitz, C. et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 78, 179–192 (2005).
Simon, D. B. et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+resorption. Science 285, 103–106 (1999).
Weber, S. et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J. Am. Soc. Nephrol. 12, 1872–1881 (2001).
Claverie-Martin, F. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin. Kidney J. 8, 656–664 (2015).
Yamaguti, P. M. et al. Amelogenesis imperfecta in familial hypomagnesaemia and hypercalciuria with nephrocalcinosis caused by CLDN19 gene mutations. J. Med. Genet. 54, 26–37 (2017).
Müller, D. et al. A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am. J. Hum. Genet. 73, 1293–1301 (2003).
Konrad, M. et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am. J. Hum. Genet. 79, 949–957 (2006).
Hou, J. et al. Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc. Natl Acad. Sci. USA 106, 15350–15355 (2009).
Hou, J. et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J. Clin. Invest. 118, 1–11 (2008).
Peng, S., Gan, G., Rao, V. S., Adelman, R. A. & Rizzolo, L. J. Effects of proinflammatory cytokines on the claudin-19 rich tight junctions of human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 53, 5016–5028 (2012).
Schlingmann, K. P. et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365, 410–421 (2011).
Molin, A. et al. CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J. Clin. Endocrinol. Metab. 100, E1343–E1352 (2015).
Sayers, J. et al. Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. Clin. Kidney J. 8, 453–455 (2015).
Peiris, E. D. & Wusirika, R. A case report of compound heterozygous CYP24A1 mutations leading to nephrolithiasis successfully treated with ketoconazole. Case Rep. Nephrol. Dial. 7, 167–171 (2018).
Hureaux, M. et al. Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations. Pediatr. Nephrol. 33, 1–7 (2018).
Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559–2570 (2015).
Lorenz, E. C., Michet, C. J., Milliner, D. S. & Lieske, J. C. Update on oxalate crystal disease. Curr. Rheumatol. Rep. 15, 1264–1269 (2013).
Pey, A. L., Salido, E. & Sanchez-Ruiz, J. M. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino Acids 41, 1233–1245 (2010).
Dhondup, T., Lorenz, E. C., Milliner, D. S. & Lieske, J. C. Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am. J. Transplant. 18, 253–257 (2018).
Cramer, S. D., Ferree, P. M., Lin, K., Milliner, D. S. & Holmes, R. P. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum. Mol. Genet. 8, 2063–2069 (1999).
Lam, C. W. et al. Novel mutation in the GRHPR gene in a Chinese patient with primary hyperoxaluria type 2 requiring renal transplantation from a living related donor. Am. J. Kidney Dis. 38, 1307–1310 (2001).
Riedel, T. J. et al. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One 6, e26021 (2011).
Monico, C. G. et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin. J. Am. Soc. Nephrol. 6, 2289–2295 (2011).
Gee, H. Y. et al. Mutations in SLC26A1 cause nephrolithiasis. Am. J. Hum. Genet. 98, 1228–1234 (2016).
Dawson, P. A. et al. Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. J. Clin. Invest. 120, 706–712 (2010).
Cochat, P. et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol. Dial. Transpl. 27, 1729–1736 (2012).
Biyani, C. S. & Cartledge, J. J. Cystinuria — diagnosis and management. EAU-EBU Update Ser. 4, 175–183 (2006).
Strologo, L. D. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J. Am. Soc. Nephrol. 13, 2547–2553 (2002).
Font-Llitjos, M. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J. Med. Genet. 42, 58–68 (2005).
Torres, R. J. & Puig, J. G. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J. Rare Dis. 2, 48 (2007).
Nyhan, W. L., James, J. A., Teberg, A. J., Sweetman, L. & Nelson, L. G. A new disorder of purine metabolism with behavioral manifestations. J. Pediatrics 74, 20–27 (1969).
Simmonds, H. A., Webster, D. R., Wilson, J. & Lingham, S. An X-linked syndrome characterised by hyperuricaemia, deafness, and neurodevelopmental abnormalities. Lancet 320, 68–70 (1982).
Zoref-Shani, E., Feinstein, S., Frishberg, Y., Bromberg, Y. & Sperling, O. Kelley-Seegmiller syndrome due to a unique variant of hypoxanthine-guanine phosphoribosyltransferase: reduced affinity for 5-phosphoribosyl-1-pyrophosphate manifested only at low, physiological substrate concentrations. Biochim. Biophys. Acta 1500, 197–203 (2000).
Zoref, E., Vries, A. D. & Sperling, O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J. Clin. Invest. 56, 1093–1099 (1975).
Roessler, B. J. et al. Human X-linked phosphoribosylpyrophosphate synthetase superactivity is associated with distinct point mutations in the PRPS1 gene. J. Biol. Chem. 268, 26476–26481 (1993).
Becker, M. A., Raivio, K. O., Bakay, B., Adams, W. B. & Nyhan, W. L. Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J. Clin. Invest. 65, 109–120 (1980).
Matsuo, H. et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am. J. Hum. Genet. 83, 744–751 (2008).
Ichida, K. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J. Am. Soc. Nephrol. 15, 164–173 (2004).
Tasic, V. et al. Clinical and functional characterization of URAT1 variants. PLoS One 6, e28641 (2011).
Dinour, D. et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J. Am. Soc. Nephrol. 21, 64–72 (2010).
Ng, N., Kaur, A. & Shenoy, M. Recurrent kidney stones in a child with Lesch-Nyhan syndrome: answers. Pediatr. Nephrol. 34, 425–427 (2019).
Bhasin, B. et al. Hereditary renal hypouricemia: a new role for allopurinol? Am. J. Med. 127, e3–e4 (2014).
Ichida, K. et al. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J. Clin. Invest. 99, 2391–2397 (1997).
Ichida, K., Matsumura, T., Sakuma, R., Hosoya, T. & Nishino, T. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem. Biophys. Res. Commun. 282, 1194–1200 (2001).
Nagae, A. et al. Asymptomatic hereditary xanthinuria: a case report. Jpn. J. Med. 29, 287–291 (1990).
Fildes, R. D. Hereditary xanthinuria with severe urolithiasis occurring in infancy as renal tubular acidosis and hypercalciuria. J. Pediatrics 115, 277–280 (1989).
Reiss, J. & Hahnewald, R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum. Mutat. 32, 10–18 (2010).
Zaki, M. S. et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: clinical and molecular spectrum among Egyptian patients. Eur. J. Paediatr. Neuro. 20, 714–722 (2016).
Runolfsdottir, H. L., Palsson, R., Agustsdottir, I. M., Indridason, O. S. & Edvardsson, V. O. Kidney disease in adenine phosphoribosyltransferase deficiency. Am. J. Kidney Dis. 67, 431–438 (2016).
Bollée, G. et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J. Am. Soc. Nephrol. 21, 679–688 (2010).
Kamatani, N., Terai, C., Kuroshima, S., Nishioka, K. & Mikanagi, K. Genetic and clinical studies on 19 families with adenine phosphoribosyltransferase deficiencies. Hum. Genet. 75, 163–168 (1987).
Edvardsson, V. O. et al. Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency (APRTd): a clinical trial. Eur. J. Intern. Med. 48, 75–79 (2018).
Jaffer, A., Joyce, A., Koenig, P. & Biyani, C. S. Adenine phosphoribosyltransferase deficiency: a rare cause of recurrent urolithiasis. J. Endourol. Case Rep. 3, 49–51 (2017).
Thorleifsson, G. et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat. Genet. 41, 926–930 (2009).
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat. Commun. 10, 5175 (2019).
Tanikawa, C. et al. Novel risk loci identified in a genome-wide association study of urolithiasis in a Japanese population. J. Am. Soc. Nephrol. 30, 855–864 (2019).
Gudbjartsson, D. F. et al. Association of variants at UMOD with chronic kidney disease and kidney stones — role of age and comorbid diseases. PLoS Genet. 6, e1001039 (2010).
Benonisdottir, S. et al. Sequence variants associating with urinary biomarkers. Hum. Mol. Genet. 28, 1199–1211 (2019).
Toka, H. R., Genovese, G., Mount, D. B., Pollak, M. R. & Curhan, G. C. Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. PLoS One 8, e71885–e71888 (2013).
Ure, M. E. et al. A variant in a cis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset hypercalciuria and kidney stones. Hum. Mutat. 38, 649–657 (2017).
Dimke, H. et al. Activation of the Ca2+-sensing receptor increases renal claudin-14 expression and urinary Ca2+ excretion. Am. J. Physiol. Renal Physiol. 304, F761–F769 (2013).
Vezzoli, G. et al. R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 71, 1155–1162 (2007).
Vezzoli, G. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J. Am. Soc. Nephrol. 13, 2517–2523 (2002).
Liu, K. et al. The G allele of CaSR R990G polymorphism increases susceptibility to urolithiasis and hypercalciuria: evidences from a comprehensive meta-analysis. Biomed. Res. Int. 2015, 958207–958212 (2015).
Petrucci, M. et al. Evaluation of the calcium-sensing receptor gene in idiopathic hypercalciuria and calcium nephrolithiasis. Kidney Int. 58, 38–42 (2000).
Li, X. et al. Common variants in ALPL gene contribute to the risk of kidney stones in the Han Chinese population. Genet. Test. Mol. Biomarkers 22, 187–192 (2018).
Whyte, M. P. Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 12, 233–246 (2016).
Hoenderop, J. G. J. et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J. Clin. Invest. 112, 1906–1914 (2003).
Loh, N. Y. et al. Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. PLoS One 8, e55412 (2013).
Wang, L., Holmes, R. P. & Peng, J.-B. The L530R variation associated with recurrent kidney stones impairs the structure and function of TRPV5. Biochem. Biophys. Res. Commun. 492, 362–367 (2017).
Renkema, K. Y. et al. TRPV5 gene polymorphisms in renal hypercalciuria. Nephrol. Dial. Transpl. 24, 1919–1924 (2009).
Khaleel, A. et al. A single nucleotide polymorphism (rs4236480) in TRPV5 calcium channel gene is associated with stone multiplicity in calcium nephrolithiasis patients. Mediators Inflamm. 2015, 375427 (2015).
Lu, X. et al. Urolithiasis/endourology in silico screening and molecular dynamic study of nonsynonymous single nucleotide polymorphisms associated with kidney stones in the SLC26A6 gene. J. Urol. 196, 118–123 (2016).
Suzuki, Y. et al. Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. Hum. Mol. Genet. 17, 1613–1618 (2008).
Jiang, Z. et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat. Genet. 38, 474–478 (2006).
Jiang, H. et al. High expression of SLC26A6 in the kidney may contribute to renal calcification via an SLC26A6-dependent mechanism. PeerJ 6, e5192 (2018).
Liu, C.-C. et al. Association of vitamin D receptor (Fok-I) polymorphism with the clinical presentation of calcium urolithiasis. BJU Int. 99, 1534–1538 (2007).
Chen, W. C., Chen, H. Y., Hsu, C. D., Wu, J. Y. & Tsai, F. J. No association of vitamin D receptor gene BsmI polymorphisms with calcium oxalate stone formation. Mol. Urol. 5, 7–10 (2001).
Gunes, S. et al. Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urol. Res. 34, 47–52 (2006).
Moyano, M. J. et al. Alterations in bone mineral metabolism in patients with calcium kidney stone disease and polymorphism of vitamin D receptor. Preliminary results. Nefrologia 27, 694–703 (2007).
Bid, H. K., Chaudhary, H. & Mittal, R. D. Association of vitamin-D and calcitonin receptor gene polymorphism in paediatric nephrolithiasis. Pediatr. Nephrol. 20, 773–776 (2005).
Jackman, S. V. et al. Familial calcium stone disease: TaqI polymorphism and the vitamin D receptor. J. Endourol. 13, 313–316 (1999).
Ruggiero, M., Pacini, S., Amato, M., Aterini, S. & Chiarugi, V. Association between vitamin D receptor gene polymorphism and nephrolithiasis. Miner. Electrolyte Metab. 25, 185–190 (1999).
Liu, W. et al. Vitamin D receptor gene (VDR) polymorphisms and the urolithiasis risk: an updated meta-analysis based on 20 case–control studies. Urolithiasis 42, 45–52 (2013).
Zhang, P., Nie, W. & Jiang, H. Effects of vitamin D receptor polymorphisms on urolithiasis risk: a meta-analysis. BMC Med. Genet. 14, 104 (2013).
Lin, H. et al. HIPK2 polymorphisms rs2058265, rs6464214, and rs7456421 were associated with kidney stone disease in Chinese males not females. Gene 653, 51–56 (2018).
Liu, C.-C. et al. The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin. Chim. Acta 411, 739–743 (2010).
Safarinejad, M. R., Shafiei, N. & Safarinejad, S. Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis. Urolithiasis 41, 303–313 (2013).
Gao, B. et al. A polymorphism of matrix Gla protein gene is associated with kidney stones. J. Urol. 177, 2361–2365 (2007).
Lu, X. et al. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511, 127–130 (2012).
Goiko, M. et al. Peptides of matrix Gla protein inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals. PLoS One 8, e80344 (2013).
Li, D. et al. Meta-analysis of the urokinase gene 3′-UTR T/C polymorphism and susceptibility to urolithiasis. Biomed. Rep. 1, 369–374 (2013).
Langman, C. B. A rational approach to the use of sophisticated genetic analyses of pediatric stone disease. Kidney Int. 93, 15–18 (2018).
The authors are supported by National Institute for Health Research (NIHR) Academic Clinical Lectureship (S.A.H.); Kidney Research UK project grant (RP_030_20180306; S.A.H.); Wellcome Trust Investigator Award (R.V.T.); NIHR Oxford Biomedical Research Centre Programme (R.V.T.); and NIHR Senior Investigator Award (R.V.T.).
The authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks G. Gambaro, T. Yasui and J. Sayer for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
gnomAD browser: https://gnomad.broadinstitute.org/
About this article
Cite this article
Howles, S.A., Thakker, R.V. Genetics of kidney stone disease. Nat Rev Urol 17, 407–421 (2020). https://doi.org/10.1038/s41585-020-0332-x
This article is cited by
BMC Microbiology (2023)
The association of dietary intake of riboflavin and thiamine with kidney stone: a cross-sectional survey of NHANES 2007–2018
BMC Public Health (2023)
Causal effects of modifiable risk factors on kidney stones: a bidirectional mendelian randomization study
BMC Medical Genomics (2023)
Causal effects of inflammatory bowel diseases on the risk of kidney stone disease: a two-sample bidirectional mendelian randomization
BMC Urology (2023)
Exosome-mediated crosstalk between epithelial cells amplifies the cell injury cascade in CaOx stone formation
Journal of Biological Engineering (2023)